111 related articles for article (PubMed ID: 37584736)
1. A national evaluation of adjuvant chemotherapy in pT4N0M0 colon cancer from the National Cancer Database.
Reif de Paula T; Keller DS
J Natl Cancer Inst; 2023 Dec; 115(12):1616-1625. PubMed ID: 37584736
[TBL] [Abstract][Full Text] [Related]
2. A national evaluation of the predictors of compliance and survival from adjuvant chemotherapy in high-risk stage II colon cancer: A National Cancer Database (NCDB) analysis.
Reif de Paula T; Gorroochurn P; Haas EM; Keller DS
Surgery; 2022 Sep; 172(3):859-868. PubMed ID: 35864050
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
4. Association of time to resection with survival in patients with colon cancer.
Sakowitz S; Bakhtiyar SS; Verma A; Ebrahimian S; Vadlakonda A; Mabeza RM; Lee H; Benharash P
Surg Endosc; 2024 Feb; 38(2):614-623. PubMed ID: 38012438
[TBL] [Abstract][Full Text] [Related]
5. Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer and Overall Survival: A National Cancer Database Study.
Enofe N; Morris AD; Liu Y; Liang W; Wu CS; Sullivan PS; Balch GG; Staley CA; Gillespie TW; Shaffer VO
J Surg Res; 2020 Aug; 252():69-79. PubMed ID: 32244127
[TBL] [Abstract][Full Text] [Related]
6. A national evaluation of the use and survival impact of adjuvant chemotherapy in Stage II colon cancer from the national cancer database.
Reif de Paula T; Gorroochurn P; Simon HL; Haas EM; Keller DS
Colorectal Dis; 2022 Jan; 24(1):40-49. PubMed ID: 34605166
[TBL] [Abstract][Full Text] [Related]
7. Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity Patients.
El Hajj J; Soleja M; Goksu SY; Ahn C; Sanford NN; Karagkounis G; Pogacnik JS; Ali F; Chilakamarry S; Kainthla R; Hsiehchen D; Jones AL; Al Mutar S; Sanjeevaiah A; Beg MS; Huang EH; Kazmi SM
Clin Colorectal Cancer; 2022 Dec; 21(4):315-324. PubMed ID: 36283915
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
[TBL] [Abstract][Full Text] [Related]
9. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations.
Hamad A; Eskander MF; Shen C; Bhattacharyya O; Fisher JL; Oppong BA; Obeng-Gyasi S; Tsung A
Surgery; 2022 Sep; 172(3):982-988. PubMed ID: 35595567
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.
O'Connor ES; Greenblatt DY; LoConte NK; Gangnon RE; Liou JI; Heise CP; Smith MA
J Clin Oncol; 2011 Sep; 29(25):3381-8. PubMed ID: 21788561
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
Casadaban L; Rauscher G; Aklilu M; Villenes D; Freels S; Maker AV
Cancer; 2016 Nov; 122(21):3277-3287. PubMed ID: 27417445
[TBL] [Abstract][Full Text] [Related]
12. Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.
Chen Y; Shankaran V; Hahn EE; Haupt EC; Bansal A
J Manag Care Spec Pharm; 2023 Jun; 29(6):635-646. PubMed ID: 37276035
[No Abstract] [Full Text] [Related]
13. N1c colon cancer and the use of adjuvant chemotherapy: a current audit of the National Cancer Database.
Simon HL; Reif de Paula T; Spigel ZA; Keller DS
Colorectal Dis; 2021 Mar; 23(3):653-663. PubMed ID: 33064353
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Receipt of Adjuvant Chemotherapy in Stage II Colon Cancer.
Ginesi MC; Bliggenstorfer JT; Kwesiga DM; Xu SH; Jodeh D; Eva Selfridge J; Stein SL; Steinhagen EF
Ann Surg Oncol; 2023 Sep; 30(9):5511-5518. PubMed ID: 37249722
[TBL] [Abstract][Full Text] [Related]
15. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
16. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
[TBL] [Abstract][Full Text] [Related]
17. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients.
Hsieh MC; Thompson T; Wu XC; Styles T; O'Flarity MB; Morris CR; Chen VW
Cancer Med; 2016 May; 5(5):871-80. PubMed ID: 26773804
[TBL] [Abstract][Full Text] [Related]
18. Sociodemographic Disparities in Access to Chemotherapy for Bladder Cancer.
Venkat S; Lewicki PJ; Khan AI; Gaffney C; Borregales L; Scherr DS
Clin Genitourin Cancer; 2022 Apr; 20(2):e140-e150. PubMed ID: 35039232
[TBL] [Abstract][Full Text] [Related]
19. Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States.
Hao S; Snyder RA; Irish W; Parikh AA
PLoS Med; 2021 Oct; 18(10):e1003842. PubMed ID: 34695123
[TBL] [Abstract][Full Text] [Related]
20. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
